Protagonist Therapeutics and Takeda secured exclusive worldwide commercialization rights for rusfertide, which was approved by the FDA for polycythemia vera in adults.

1 report, 1 independent Updated Sep 4

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA

Keep exploring

Part of

Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating. All 1 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Sep 4insidermonkey.com